Press release

DSM announces repurchase of shares to cover existing option plans and stock dividend

Heerlen, NL, 22 Feb 2016 08:00 CET

Royal DSM, a global science-based company active in health, nutrition and materials, today announces that it intends to repurchase 3,200,000 ordinary shares, starting on 22 February 2016, in order to cover its commitments under existing management and personnel option plans (2,500,000) and shares for stock dividend as part of the final dividend 2015 (700,000). Based on the closing price of the DSM share on Euronext Amsterdam on 19 February 2016 this would be equivalent to approximately €140 million.

DSM has signed a Discretionary Management Agreement with the bank that will execute the repurchase. The repurchase price will be based on the daily VWAP (Volume Weighted Average Price). Volumes to be repurchased will be on average 5% of the daily trading volume on the open market, within a bandwidth of 2-8% per day. This share repurchase program is anticipated to continue into Q2 2016. The total number of shares to be repurchased under this program represents approximately 1.76% of ordinary shares issued.

In accordance with regulations DSM will inform the market about the progress made in the execution of this program through weekly press releases.

Statement pursuant to art. 5:25a of the Dutch Financial Supervision Act

DSM also announces that The Netherlands is its “Home Member State”, as required by article 5:25a (2) of the Dutch Financial Supervision Act. This article obliges all listed companies to publicly announce which country is their "home member state" (as referred to in article 5:25a(1) sub c of the Dutch Financial Supervision Act) for purposes of regulation of their disclosure obligations under the EU Transparency Directive. Pursuant to section 5:25a of the Dutch Financial Supervision Act Royal DSM has notified the Autoriteit Financiële Markten (AFM).

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice President Investor Relations
+31 45 578 2864

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864